English
简体中文
Total: £ 56.28
Published Date: 2026-01-22 | Pages: 109 | Tables: 103 | Medical Care
The global Value-added Medicines (VAM) Development Service market was valued at US$ 638 million in 2025 and is anticipated to reach US$ 1269 million by 2032, at a CAGR of 10.5% from 2026 to 2032.
Value-added Medicines Development Service usually refers to adding additional value to pharmaceutical products by providing professional technical support, innovative solutions and optimized processes in the drug development and manufacturing process. These services may include the design, synthesis, analysis, optimization, production, quality control and other aspects of drug development to improve drug efficacy, safety, production efficiency and patient experience.
The North American market for Value-added Medicines (VAM) Development Service is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Value-added Medicines (VAM) Development Service is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Value-added Medicines (VAM) Development Service in Pharmaceutical Companies is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Value-added Medicines (VAM) Development Service include Altus Drug Development, TIEFENBACHER GROUP, Hyloris Pharmaceuticals SA, Adamed, Colonis, Towa International, Galenicap, Sandoz AG, Adragos Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Value-added Medicines (VAM) Development Service market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Value-added Medicines (VAM) Development Service. The Value-added Medicines (VAM) Development Service market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Value-added Medicines (VAM) Development Service market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Value-added Medicines (VAM) Development Service manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Altus Drug Development
TIEFENBACHER GROUP
Hyloris Pharmaceuticals SA
Adamed
Colonis
Towa International
Galenicap
Sandoz AG
Adragos Pharma
Segment by Type
Chronic Disease Treatment Drugs
Infectious Disease Treatment Drugs
Tumor Treatment Drugs
Other
Segment by Application
Pharmaceutical Companies
Biotech Companies
Hospitals and Medical Institutions
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Rest of Asia
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Rest of Latin America
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Rest of MEA
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Value-added Medicines (VAM) Development Service companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Value-added Medicines (VAM) Development Service Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Chronic Disease Treatment Drugs
1.2.3 Infectious Disease Treatment Drugs
1.2.4 Tumor Treatment Drugs
1.2.5 Other
1.3 Market by Application
1.3.1 Global Value-added Medicines (VAM) Development Service Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Pharmaceutical Companies
1.3.3 Biotech Companies
1.3.4 Hospitals and Medical Institutions
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Value-added Medicines (VAM) Development Service Market Perspective (2021–2032)
2.2 Global Value-added Medicines (VAM) Development Service Growth Trends by Region
2.2.1 Global Value-added Medicines (VAM) Development Service Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Value-added Medicines (VAM) Development Service Historic Market Size by Region (2021–2026)
2.2.3 Value-added Medicines (VAM) Development Service Forecasted Market Size by Region (2027–2032)
2.3 Value-added Medicines (VAM) Development Service Market Dynamics
2.3.1 Value-added Medicines (VAM) Development Service Industry Trends
2.3.2 Value-added Medicines (VAM) Development Service Market Drivers
2.3.3 Value-added Medicines (VAM) Development Service Market Challenges
2.3.4 Value-added Medicines (VAM) Development Service Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Value-added Medicines (VAM) Development Service Players by Revenue
3.1.1 Global Top Value-added Medicines (VAM) Development Service Players by Revenue (2021–2026)
3.1.2 Global Value-added Medicines (VAM) Development Service Revenue Market Share by Players (2021–2026)
3.2 Global Top Value-added Medicines (VAM) Development Service Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Value-added Medicines (VAM) Development Service Revenue
3.4 Global Value-added Medicines (VAM) Development Service Market Concentration Ratio
3.4.1 Global Value-added Medicines (VAM) Development Service Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Value-added Medicines (VAM) Development Service Revenue in 2025
3.5 Global Key Players of Value-added Medicines (VAM) Development Service Head Offices and Areas Served
3.6 Global Key Players of Value-added Medicines (VAM) Development Service, Products and Applications
3.7 Global Key Players of Value-added Medicines (VAM) Development Service, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Value-added Medicines (VAM) Development Service Breakdown Data by Type
4.1 Global Value-added Medicines (VAM) Development Service Historic Market Size by Type (2021–2026)
4.2 Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Type (2027–2032)
5 Value-added Medicines (VAM) Development Service Breakdown Data by Application
5.1 Global Value-added Medicines (VAM) Development Service Historic Market Size by Application (2021–2026)
5.2 Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Value-added Medicines (VAM) Development Service Market Size (2021–2032)
6.2 North America Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Value-added Medicines (VAM) Development Service Market Size by Country (2021–2026)
6.4 North America Value-added Medicines (VAM) Development Service Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Value-added Medicines (VAM) Development Service Market Size (2021–2032)
7.2 Europe Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Value-added Medicines (VAM) Development Service Market Size by Country (2021–2026)
7.4 Europe Value-added Medicines (VAM) Development Service Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Value-added Medicines (VAM) Development Service Market Size (2021–2032)
8.2 Asia-Pacific Value-added Medicines (VAM) Development Service Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (2021–2026)
8.4 Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Value-added Medicines (VAM) Development Service Market Size (2021–2032)
9.2 Latin America Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Value-added Medicines (VAM) Development Service Market Size by Country (2021–2026)
9.4 Latin America Value-added Medicines (VAM) Development Service Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Value-added Medicines (VAM) Development Service Market Size (2021–2032)
10.2 Middle East & Africa Value-added Medicines (VAM) Development Service Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (2021–2026)
10.4 Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Altus Drug Development
11.1.1 Altus Drug Development Company Details
11.1.2 Altus Drug Development Business Overview
11.1.3 Altus Drug Development Value-added Medicines (VAM) Development Service Introduction
11.1.4 Altus Drug Development Revenue in Value-added Medicines (VAM) Development Service Business (2021–2026)
11.1.5 Altus Drug Development Recent Development
11.2 TIEFENBACHER GROUP
11.2.1 TIEFENBACHER GROUP Company Details
11.2.2 TIEFENBACHER GROUP Business Overview
11.2.3 TIEFENBACHER GROUP Value-added Medicines (VAM) Development Service Introduction
11.2.4 TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Development Service Business (2021–2026)
11.2.5 TIEFENBACHER GROUP Recent Development
11.3 Hyloris Pharmaceuticals SA
11.3.1 Hyloris Pharmaceuticals SA Company Details
11.3.2 Hyloris Pharmaceuticals SA Business Overview
11.3.3 Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Development Service Introduction
11.3.4 Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Development Service Business (2021–2026)
11.3.5 Hyloris Pharmaceuticals SA Recent Development
11.4 Adamed
11.4.1 Adamed Company Details
11.4.2 Adamed Business Overview
11.4.3 Adamed Value-added Medicines (VAM) Development Service Introduction
11.4.4 Adamed Revenue in Value-added Medicines (VAM) Development Service Business (2021–2026)
11.4.5 Adamed Recent Development
11.5 Colonis
11.5.1 Colonis Company Details
11.5.2 Colonis Business Overview
11.5.3 Colonis Value-added Medicines (VAM) Development Service Introduction
11.5.4 Colonis Revenue in Value-added Medicines (VAM) Development Service Business (2021–2026)
11.5.5 Colonis Recent Development
11.6 Towa International
11.6.1 Towa International Company Details
11.6.2 Towa International Business Overview
11.6.3 Towa International Value-added Medicines (VAM) Development Service Introduction
11.6.4 Towa International Revenue in Value-added Medicines (VAM) Development Service Business (2021–2026)
11.6.5 Towa International Recent Development
11.7 Galenicap
11.7.1 Galenicap Company Details
11.7.2 Galenicap Business Overview
11.7.3 Galenicap Value-added Medicines (VAM) Development Service Introduction
11.7.4 Galenicap Revenue in Value-added Medicines (VAM) Development Service Business (2021–2026)
11.7.5 Galenicap Recent Development
11.8 Sandoz AG
11.8.1 Sandoz AG Company Details
11.8.2 Sandoz AG Business Overview
11.8.3 Sandoz AG Value-added Medicines (VAM) Development Service Introduction
11.8.4 Sandoz AG Revenue in Value-added Medicines (VAM) Development Service Business (2021–2026)
11.8.5 Sandoz AG Recent Development
11.9 Adragos Pharma
11.9.1 Adragos Pharma Company Details
11.9.2 Adragos Pharma Business Overview
11.9.3 Adragos Pharma Value-added Medicines (VAM) Development Service Introduction
11.9.4 Adragos Pharma Revenue in Value-added Medicines (VAM) Development Service Business (2021–2026)
11.9.5 Adragos Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Value-added Medicines (VAM) Development Service Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of Chronic Disease Treatment Drugs
Table 3. Key Players of Infectious Disease Treatment Drugs
Table 4. Key Players of Tumor Treatment Drugs
Table 5. Key Players of Other
Table 6. Global Value-added Medicines (VAM) Development Service Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 7. Global Value-added Medicines (VAM) Development Service Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 8. Global Value-added Medicines (VAM) Development Service Market Size by Region (US$ Million), 2021–2026
Table 9. Global Value-added Medicines (VAM) Development Service Market Share by Region (2021–2026)
Table 10. Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Region (US$ Million), 2027–2032
Table 11. Global Value-added Medicines (VAM) Development Service Market Share by Region (2027–2032)
Table 12. Value-added Medicines (VAM) Development Service Market Trends
Table 13. Value-added Medicines (VAM) Development Service Market Drivers
Table 14. Value-added Medicines (VAM) Development Service Market Challenges
Table 15. Value-added Medicines (VAM) Development Service Market Restraints
Table 16. Global Value-added Medicines (VAM) Development Service Revenue by Players (US$ Million), 2021–2026
Table 17. Global Value-added Medicines (VAM) Development Service Market Share by Players (2021–2026)
Table 18. Global Top Value-added Medicines (VAM) Development Service Players by Tier (Tier 1, Tier 2, and Tier 3), based on Value-added Medicines (VAM) Development Service Revenue, 2025
Table 19. Ranking of Global Top Value-added Medicines (VAM) Development Service Companies by Revenue (US$ Million) in 2025
Table 20. Global 5 Largest Players Market Share by Value-added Medicines (VAM) Development Service Revenue (CR5 and HHI), 2021–2026
Table 21. Global Key Players of Value-added Medicines (VAM) Development Service, Headquarters and Area Served
Table 22. Global Key Players of Value-added Medicines (VAM) Development Service, Products and Applications
Table 23. Global Key Players of Value-added Medicines (VAM) Development Service, Date of General Availability (GA)
Table 24. Mergers and Acquisitions, Expansion Plans
Table 25. Global Value-added Medicines (VAM) Development Service Market Size by Type (US$ Million), 2021–2026
Table 26. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Type (2021–2026)
Table 27. Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Type (US$ Million), 2027–2032
Table 28. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Type (2027–2032)
Table 29. Global Value-added Medicines (VAM) Development Service Market Size by Application (US$ Million), 2021–2026
Table 30. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Application (2021–2026)
Table 31. Global Value-added Medicines (VAM) Development Service Forecasted Market Size by Application (US$ Million), 2027–2032
Table 32. Global Value-added Medicines (VAM) Development Service Revenue Market Share by Application (2027–2032)
Table 33. North America Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 34. North America Value-added Medicines (VAM) Development Service Market Size by Country (US$ Million), 2021–2026
Table 35. North America Value-added Medicines (VAM) Development Service Market Size by Country (US$ Million), 2027–2032
Table 36. Europe Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 37. Europe Value-added Medicines (VAM) Development Service Market Size by Country (US$ Million), 2021–2026
Table 38. Europe Value-added Medicines (VAM) Development Service Market Size by Country (US$ Million), 2027–2032
Table 39. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 40. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (US$ Million), 2021–2026
Table 41. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size by Region (US$ Million), 2027–2032
Table 42. Latin America Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 43. Latin America Value-added Medicines (VAM) Development Service Market Size by Country (US$ Million), 2021–2026
Table 44. Latin America Value-added Medicines (VAM) Development Service Market Size by Country (US$ Million), 2027–2032
Table 45. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 46. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (US$ Million), 2021–2026
Table 47. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size by Country (US$ Million), 2027–2032
Table 48. Altus Drug Development Company Details
Table 49. Altus Drug Development Business Overview
Table 50. Altus Drug Development Value-added Medicines (VAM) Development Service Product
Table 51. Altus Drug Development Revenue in Value-added Medicines (VAM) Development Service Business (US$ Million), 2021–2026
Table 52. Altus Drug Development Recent Development
Table 53. TIEFENBACHER GROUP Company Details
Table 54. TIEFENBACHER GROUP Business Overview
Table 55. TIEFENBACHER GROUP Value-added Medicines (VAM) Development Service Product
Table 56. TIEFENBACHER GROUP Revenue in Value-added Medicines (VAM) Development Service Business (US$ Million), 2021–2026
Table 57. TIEFENBACHER GROUP Recent Development
Table 58. Hyloris Pharmaceuticals SA Company Details
Table 59. Hyloris Pharmaceuticals SA Business Overview
Table 60. Hyloris Pharmaceuticals SA Value-added Medicines (VAM) Development Service Product
Table 61. Hyloris Pharmaceuticals SA Revenue in Value-added Medicines (VAM) Development Service Business (US$ Million), 2021–2026
Table 62. Hyloris Pharmaceuticals SA Recent Development
Table 63. Adamed Company Details
Table 64. Adamed Business Overview
Table 65. Adamed Value-added Medicines (VAM) Development Service Product
Table 66. Adamed Revenue in Value-added Medicines (VAM) Development Service Business (US$ Million), 2021–2026
Table 67. Adamed Recent Development
Table 68. Colonis Company Details
Table 69. Colonis Business Overview
Table 70. Colonis Value-added Medicines (VAM) Development Service Product
Table 71. Colonis Revenue in Value-added Medicines (VAM) Development Service Business (US$ Million), 2021–2026
Table 72. Colonis Recent Development
Table 73. Towa International Company Details
Table 74. Towa International Business Overview
Table 75. Towa International Value-added Medicines (VAM) Development Service Product
Table 76. Towa International Revenue in Value-added Medicines (VAM) Development Service Business (US$ Million), 2021–2026
Table 77. Towa International Recent Development
Table 78. Galenicap Company Details
Table 79. Galenicap Business Overview
Table 80. Galenicap Value-added Medicines (VAM) Development Service Product
Table 81. Galenicap Revenue in Value-added Medicines (VAM) Development Service Business (US$ Million), 2021–2026
Table 82. Galenicap Recent Development
Table 83. Sandoz AG Company Details
Table 84. Sandoz AG Business Overview
Table 85. Sandoz AG Value-added Medicines (VAM) Development Service Product
Table 86. Sandoz AG Revenue in Value-added Medicines (VAM) Development Service Business (US$ Million), 2021–2026
Table 87. Sandoz AG Recent Development
Table 88. Adragos Pharma Company Details
Table 89. Adragos Pharma Business Overview
Table 90. Adragos Pharma Value-added Medicines (VAM) Development Service Product
Table 91. Adragos Pharma Revenue in Value-added Medicines (VAM) Development Service Business (US$ Million), 2021–2026
Table 92. Adragos Pharma Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
Table 96. Authors List of This Report
List of Figures
Figure 1. Value-added Medicines (VAM) Development Service Picture
Figure 2. Global Value-added Medicines (VAM) Development Service Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Value-added Medicines (VAM) Development Service Market Share by Type: 2025 vs 2032
Figure 4. Chronic Disease Treatment Drugs Features
Figure 5. Infectious Disease Treatment Drugs Features
Figure 6. Tumor Treatment Drugs Features
Figure 7. Other Features
Figure 8. Global Value-added Medicines (VAM) Development Service Market Size by Application (US$ Million), 2021–2032
Figure 9. Global Value-added Medicines (VAM) Development Service Market Share by Application: 2025 vs 2032
Figure 10. Pharmaceutical Companies Case Studies
Figure 11. Biotech Companies Case Studies
Figure 12. Hospitals and Medical Institutions Case Studies
Figure 13. Value-added Medicines (VAM) Development Service Report Years Considered
Figure 14. Global Value-added Medicines (VAM) Development Service Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 15. Global Value-added Medicines (VAM) Development Service Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 16. Global Value-added Medicines (VAM) Development Service Market Share by Region: 2025 vs 2032
Figure 17. Global Value-added Medicines (VAM) Development Service Market Share by Players in 2025
Figure 18. Global Value-added Medicines (VAM) Development Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 19. The Top 10 and 5 Players Market Share by Value-added Medicines (VAM) Development Service Revenue in 2025
Figure 20. North America Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 21. North America Value-added Medicines (VAM) Development Service Market Share by Country (2021–2032)
Figure 22. United States Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 23. Canada Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. Europe Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. Europe Value-added Medicines (VAM) Development Service Market Share by Country (2021–2032)
Figure 26. Germany Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. France Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. U.K. Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Italy Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Russia Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 31. Ireland Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Asia-Pacific Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. Asia-Pacific Value-added Medicines (VAM) Development Service Market Share by Region (2021–2032)
Figure 34. China Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. Japan Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. South Korea Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Southeast Asia Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. India Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 39. Australia & New Zealand Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Latin America Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Latin America Value-added Medicines (VAM) Development Service Market Share by Country (2021–2032)
Figure 42. Mexico Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 43. Brazil Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Middle East & Africa Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. Middle East & Africa Value-added Medicines (VAM) Development Service Market Share by Country (2021–2032)
Figure 46. Israel Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 47. Saudi Arabia Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 48. UAE Value-added Medicines (VAM) Development Service Market Size YoY Growth (US$ Million), 2021–2032
Figure 49. Altus Drug Development Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2021–2026)
Figure 50. TIEFENBACHER GROUP Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2021–2026)
Figure 51. Hyloris Pharmaceuticals SA Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2021–2026)
Figure 52. Adamed Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2021–2026)
Figure 53. Colonis Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2021–2026)
Figure 54. Towa International Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2021–2026)
Figure 55. Galenicap Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2021–2026)
Figure 56. Sandoz AG Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2021–2026)
Figure 57. Adragos Pharma Revenue Growth Rate in Value-added Medicines (VAM) Development Service Business (2021–2026)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
